Advances in Developing Small Molecule Drugs for Alzheimer's Disease

Overview

Journal Curr Alzheimer Res

Publisher Bentham Science Publishers

Specialty Neurology

Date 2024 Aug 13

PMID 39136501

Authors

Wei Zhang

Liujie Zhang

Mingti Lv

Yun Fu

Xiaowen Meng

Mingyong Wang

Hecheng Wang

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is the most common type of dementia among middle-aged and elderly individuals. Accelerating the prevention and treatment of AD has become an urgent problem. New technology including Computer-aided drug design (CADD) can effectively reduce the medication cost for patients with AD, reduce the cost of living, and improve the quality of life of patients, providing new ideas for treating AD. This paper reviews the pathogenesis of AD, the latest developments in CADD and other small-molecule docking technologies for drug discovery and development; the current research status of small-molecule compounds for AD at home and abroad from the perspective of drug action targets; the future of AD drug development.

References

Tatulian S . Challenges and hopes for Alzheimer's disease. Drug Discov Today. 2022; 27(4):1027-1043. DOI: 10.1016/j.drudis.2022.01.016. View

Adav S, Sze S . Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling. Mol Brain. 2016; 9(1):92. PMC: 5094070. DOI: 10.1186/s13041-016-0272-9. View

Peng C, Trojanowski J, Lee V . Protein transmission in neurodegenerative disease. Nat Rev Neurol. 2020; 16(4):199-212. PMC: 9242841. DOI: 10.1038/s41582-020-0333-7. View

. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023; 19(4):1598-1695. DOI: 10.1002/alz.13016. View

. 2022 Alzheimer's disease facts and figures. Alzheimers Dement. 2022; 18(4):700-789. DOI: 10.1002/alz.12638. View

Yiannopoulou K, Papageorgiou S . Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis. 2020; 12:1179573520907397. PMC: 7050025. DOI: 10.1177/1179573520907397. View

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396(10248):413-446. PMC: 7392084. DOI: 10.1016/S0140-6736(20)30367-6. View

Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K . Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement (N Y). 2019; 5:272-293. PMC: 6617248. DOI: 10.1016/j.trci.2019.05.008. View

Shukla R, Singh T . Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease. J Biomol Struct Dyn. 2019; 38(1):248-262. DOI: 10.1080/07391102.2019.1571947. View

10.

Mouchlis V, Melagraki G, Zacharia L, Afantitis A . Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics. Int J Mol Sci. 2020; 21(3). PMC: 7038192. DOI: 10.3390/ijms21030703. View

11.

Jabir N, Rehman M, Alsolami K, Shakil S, Zughaibi T, Alserihi R . Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: in pursuit of Alzheimer's treatment. Ann Med. 2021; 53(1):2332-2344. PMC: 8667905. DOI: 10.1080/07853890.2021.2009124. View

12.

Griffiths J, Grant S . Synapse pathology in Alzheimer's disease. Semin Cell Dev Biol. 2022; 139:13-23. DOI: 10.1016/j.semcdb.2022.05.028. View

13.

Ashrafian H, Zadeh E, Khan R . Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol. 2020; 167:382-394. DOI: 10.1016/j.ijbiomac.2020.11.192. View

14.

Trejo-Lopez J, Yachnis A, Prokop S . Neuropathology of Alzheimer's Disease. Neurotherapeutics. 2021; 19(1):173-185. PMC: 9130398. DOI: 10.1007/s13311-021-01146-y. View

15.

Thal D, Tome S . The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull. 2022; 190:204-217. DOI: 10.1016/j.brainresbull.2022.10.006. View

16.

Karran E, De Strooper B . The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022; 21(4):306-318. DOI: 10.1038/s41573-022-00391-w. View

17.

Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L . Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond. Transl Neurodegener. 2022; 11(1):18. PMC: 8932191. DOI: 10.1186/s40035-022-00292-3. View

18.

Zhang Y, Chen H, Li R, Sterling K, Song W . Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future. Signal Transduct Target Ther. 2023; 8(1):248. PMC: 10310781. DOI: 10.1038/s41392-023-01484-7. View

19.

Bellenguez C, Grenier-Boley B, Lambert J . Genetics of Alzheimer's disease: where we are, and where we are going. Curr Opin Neurobiol. 2019; 61:40-48. DOI: 10.1016/j.conb.2019.11.024. View

20.

Bordone M, Salman M, Titus H, Amini E, Andersen J, Chakraborti B . The energetic brain - A review from students to students. J Neurochem. 2019; 151(2):139-165. DOI: 10.1111/jnc.14829. View